# GAIA BioMedicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gaia-biomedicine

- Industry: Pharmaceuticals
- Headquarters: Fukuoka-shi, Japan
- Website: www.gaia-biomed.com
- Total disclosed funding: $13M
- Latest round: Series B (Sep 21, 2021)
- Investors on record: 4

## About

Founded in 2015 and based in Fukuoka, Japan, GAIA BioMedicine Inc. as a spin-off venture of Kyushu University, is a biopharmaceutical company that uses technology and specializes in cell therapies and immunotherapies. 
Yoshikazu Yonemitsu, MD, PhD is a professor at the R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences, Kyushu University. After working in the vascular surgery unit at Kyushu University Hospital, he served at the Gene Therapy Department of Imperial College London as a Wellcome Trust Fellow. He specializes in oncology, gene and cell therapy, and cardiovascular medicine and helped establish GAIA BioMedicine in October 2015.

GAIA BioMedicine Inc. enables the production of NK-like cells that effectively eliminate solid tumors. The company also provides GAAAP, a peptide platform that allows GAIA NK-like cells to maintain their active state and target specific proteins (e.g., HER2) that are expressed by cancer cells.  
The raised financing will support clinical trials targeting solid tumors, and expedite the GAIA 102 platform.

## Funding rounds

- Series B, Sep 21, 2021, $12M — SBI Investment, Osaka University Venture Capital, CEJ Capital, Hisamitsu Pharmaceutical Co., Inc.
- Series B, Jun 4, 2021, $0.9M — Osaka University Venture Capital

## Investors

- Osaka University Venture Capital (https://capitalatlas.ai/funds/osaka-university-venture-capital) — Series B
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series B
- CEJ Capital (https://capitalatlas.ai/funds/cej-capital) — Series B
- Hisamitsu Pharmaceutical Co., Inc. — Series B